It's interesting that SVR rates are higher in participants with acute HCV than in chronic HCV. And that in turn makes me wonder how many forum members we have that are acute HCV+ due to chemicals, drug overdose, poisons etc. etc. as opposed to chronic HCV with cirrhosis etc. which I presume includes the majority of members on this forum. (correct me if I'm wrong). Other than that comparison, I guess I'm just missing the point other than (all other factors equal) Peg / riba works better when combined with telaprevir. The title says Telaprevir made SVR quicker in co-infected MSM patients. Then it clarifies that this happens when Telaprevir is added to a Tx containing peginterferon and ribavirin in one group vs peg / riba alone in the other group. I would think that, adding Telaprevir to peg and riba would have similar results whether it's being used in co-infected / mono-infected, MSM / non MSM and regardless of incidence of HCV infection.
I see no relation between how peg / riba works better when telaprevir is added vs a rapid infection rate in this segment of society. There are other reasons why the infection rate is high in MSM's that have nothing to do with Telaprevir / peg or riba.
If I'm reading it right, all the participants are co-infected MSM's, and there are NO non-MSM, mono-infected participants included to get those results from for comparison. Again, I suspect the point is only with the difference between Tx's effectiveness on HCV in Acute vs chronic cases. And this report being a year old with better DAA's out now, the acute cases ought to be rolling in SVR's in very short Tx duration time.
hrsetrdr said
Oct 16, 2014
Mike, if I read the article correctly the reason for the focus on HIV co-infected MSM sexually active patients was due to the finding of the Multicenter AIDS Cohort Study that within this group there was an 8.5-fold higher incidence of HCV infection. See this page.
wmlj1960 said
Oct 13, 2014
I don't understand what is the significance of the fact the test subjects are HIV co-infected, much less MSM sexually active. I know this is almost a year old, but that should not be a factor concerning my question. The way I see it, I suspect adding telaprevir to a peginterferon / riba regimen would give similar results regardless of HIV status or type of sexual encounters.
The "old" SOC's continue to benefit and hold hope for the co-infected!
"Adding telaprevir to pegylated interferon and ribavirin for the treatment of acute genotype 1 hepatitis C infection in HIV-positive men reduced the duration of hepatitis C therapy by half for most patients and improved sustained virologic response rates, according to new data".
It's interesting that SVR rates are higher in participants with acute HCV than in chronic HCV. And that in turn makes me wonder how many forum members we have that are acute HCV+ due to chemicals, drug overdose, poisons etc. etc. as opposed to chronic HCV with cirrhosis etc. which I presume includes the majority of members on this forum. (correct me if I'm wrong). Other than that comparison, I guess I'm just missing the point other than (all other factors equal) Peg / riba works better when combined with telaprevir. The title says Telaprevir made SVR quicker in co-infected MSM patients. Then it clarifies that this happens when Telaprevir is added to a Tx containing peginterferon and ribavirin in one group vs peg / riba alone in the other group. I would think that, adding Telaprevir to peg and riba would have similar results whether it's being used in co-infected / mono-infected, MSM / non MSM and regardless of incidence of HCV infection.
I see no relation between how peg / riba works better when telaprevir is added vs a rapid infection rate in this segment of society. There are other reasons why the infection rate is high in MSM's that have nothing to do with Telaprevir / peg or riba.
If I'm reading it right, all the participants are co-infected MSM's, and there are NO non-MSM, mono-infected participants included to get those results from for comparison. Again, I suspect the point is only with the difference between Tx's effectiveness on HCV in Acute vs chronic cases. And this report being a year old with better DAA's out now, the acute cases ought to be rolling in SVR's in very short Tx duration time.
Mike, if I read the article correctly the reason for the focus on HIV co-infected MSM sexually active patients was due to the finding of the Multicenter AIDS Cohort Study that within this group there was an 8.5-fold higher incidence of HCV infection. See this page.
I don't understand what is the significance of the fact the test subjects are HIV co-infected, much less MSM sexually active. I know this is almost a year old, but that should not be a factor concerning my question. The way I see it, I suspect adding telaprevir to a peginterferon / riba regimen would give similar results regardless of HIV status or type of sexual encounters.
What am I missing here?
The "old" SOC's continue to benefit and hold hope for the co-infected!
"Adding telaprevir to pegylated interferon and ribavirin for the treatment of acute genotype 1 hepatitis C infection in HIV-positive men reduced the duration of hepatitis C therapy by half for most patients and improved sustained virologic response rates, according to new data".
Telaprevir reduced HCV treatment duration in HIV-coinfected patients
Tig